Terazosin polymorph and pharmaceutical composition
CA 2107382 C · Owner: Abbott Laboratories · Inventors: Bauer, John F.; Meyer, Glenn A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel anhydrous crystalline polymorph of 1-(4-amino-6,7-dimethoxy-2quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine monohydrochloride is disclosed together with pharmaceutical formulations containing the compound. The novel polymorph exhibits a diminished food effect when administered to human subjects.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 30, 1993 and granted June 3, 1997. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 30, 2013.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 30, 2015.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.